Abstract
Atherosclerosis is a complex inflammatory disease characterized by lipid accumulation within the artery walls. It produces the narrowing of arteries due to the development of intimal plaques. The formation of plaques involves the deposition of small cholesterol crystals in the intima and its underlying smooth muscle. The growth of plaques starts with the proliferation of fibrous tissues and the surrounding smooth muscle producing a bulge inside the arteries. It results in reduction of the blood flow to the heart leading to cardiovascular disease, the leading cause of mortality and morbidity worldwide. Atherosclerosis and cardiovascular disease are not only accompanied by increased levels of cholesterol, cholesterol metabolites, and trimethylamine N-oxide levels in the blood, but also by the involvement of the immune system, which is made up of many cell types, hundreds of bioactive cytokines and chemokines (TNF-α, IL-1β, IL-6, MCP-1), and millions of different antigens. This makes the development of atherosclerosis very challenging. In addition to the development of myocardial infarctions, atherosclerosis is also associated with peripheral artery disease. This pathological condition is also accompanied by different stages of atherogenesis, dyslipidemia, hypertension, oxidative stress, endothelial dysfunction, and inflammation. At the molecular level, these processes involve the generation of reactive oxygen species, reduction in redox status, and increased expression of pro-inflammatory cytokines and chemokines. These mediators can be used as biomarkers for cardiovascular disease, as well as peripheral artery disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Shah PK, Lecis D (2019) Inflammation in atherosclerotic cardiovascular disease. F1000Res. 8:F1000 faculty Rev-1402.
Rafieian-Kopaei M, Setorki M, Doudi M, et al. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5:927–46.
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.
Roth GA, Forouzanfar MH, Moran AE, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. 2015;372:1333–41.
Mendelsohn AR, Larrick JW. Dietary modification of the microbiome affects risk for cardiovascular disease. Rejuvenation Res. 2013;16:241–4.
Das M, Das DK. Resveratrol and cardiovascular health. Mol Asp Med. 2010;31:503–12.
Loftus I. In: Fitridge R, Thompson M, editors. Mechanisms of vascular disease in a reference book for vascular specialists (internet). Adelaide, Australia: University of Adelaide Press; 2011.
Ahotupa M. Oxidized lipoprotein lipids and atherosclerosis. Free Radic Res. 2017;51:439–47.
Zmysłowski A, Szterk A. Current knowledge on the mechanism of atherosclerosis and pro-atherosclerotic properties of oxysterols. Clin Chim Acta. 2019;491:103–13.
Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664–72.
Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000;31:40–7.
Casscells W, Naghavi M, Willerson JT. Vulnerable atherosclerotic plaque: a multifocal disease. Circulation. 2003;107:2072–5.
Liu Y, Yu H, Zhang Y, et al. TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target. Med Hypotheses. 2008;70:314–6.
Kockx MM, Herman AG. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc Res. 2000;45:736–46.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
Bentzon JF, Otsuka F, Virmani R, et al. Mechanisms of plaque formation and rupture. Circ Res. 2014;114:1852–66.
Scioli MG, Storti G, D’Amico F, et al. Oxidative stress and new Pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J Clin Med. 2020;9:1995.
Ellulu MS, Patimah I, Khaza’ai H, et al. Atherosclerotic cardiovascular disease: a review of initiators and protective factors. Inflammopharmacol. 2016;24:1–10.
Townsend MK, Aschard H, De Vivo I, et al. Genomics, telomere length, epigenetics, and metabolomics in the nurses’, health studies. Am. J. Public Health. 2016;106:1663–8.
Ma J, Li H. The role of gut microbiota in atherosclerosis and hypertension. Front Pharmcol. 2018;9:1082.
Farooqui AA. High calorie diet and the human brain. New York: Springer; 2015.
Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92:785–92.
Qi X, Qin L, Du R, et al. Lipopolysaccharide upregulated intestinal epithelial cell expression of Fn14 and activation of Fn14 signaling amplify intestinal TLR4-mediated inflammation. Front Cell Infect Microbiol. 2017;7:315.
Ahmadmehrabi S, Tang WHW. Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. 2017;32:761–6.
Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163:1585–95.
Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. Int J Mol Sci. 2015;16:11294–322.
Signorelli SS, Scuto S, Marino E, Xourafa A, Gaudio A. Oxidative stress in peripheral arterial disease (PAD) mechanism and biomarkers. Antioxidants (Basel). 2019;8:367.
Ismaeel A, Papoutsi E, Miserlis D, et al (2020) The nitric oxide system in peripheral artery disease: connection with oxidative stress and Biopterins. Antioxidants (Basel). 9:590.
Green DJ, Dawson EA, Groenewoud HM, Jones H, Thijssen DH. Is flow-mediated dilation nitric oxide mediated? A meta-analysis. Hypertension. 2014;63:376–82.
Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients with peripheral artery disease: a review. Vasc Med. 2011;16:203–11.
Gokce N, Keaney JF Jr, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769–75.
Steven S, Daiber A, Dopheide JF, et al. Peripheral artery disease, redox signaling, oxidative stress-basic and clinical aspects. Redox Biol. 2017;12:787–97.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Farooqui, A.A. (2021). Role of Dyslipidemia in Atherosclerosis. In: Lee, SH., Kang, M.K. (eds) Stroke Revisited: Dyslipidemia in Stroke. Stroke Revisited. Springer, Singapore. https://doi.org/10.1007/978-981-16-3923-4_1
Download citation
DOI: https://doi.org/10.1007/978-981-16-3923-4_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-3922-7
Online ISBN: 978-981-16-3923-4
eBook Packages: MedicineMedicine (R0)